

Resource Summary Report

Generated by [nidm-terms](#) on Aug 3, 2026

Cystic Fibrosis Foundation

RRID:SCR_010726

Type: Tool

Proper Citation

Cystic Fibrosis Foundation (RRID:SCR_010726)

Resource Information

URL: <http://www.cff.org/>

Proper Citation: Cystic Fibrosis Foundation (RRID:SCR_010726)

Description: The mission of the Cystic Fibrosis Foundation, a nonprofit donor-supported organization, is to assure the development of the means to cure and control cystic fibrosis and to improve the quality of life for those with the disease. The Foundation is the leading organization in the United States devoted to cystic fibrosis. It funds and accredits more than 115 CF care centers, 95 adult care programs and 50 affiliate programs, and more than 75 chapters and branch offices nationwide. The Cystic Fibrosis Foundation is one of the most efficient organizations of its kind and is an accredited charity of the Better Business Bureau's Wise Giving Alliance. Until we conquer this disease, our team will work tirelessly to extend and enhance life for those with cystic fibrosis by functioning as: * Scientific pioneers, blazing new trails in CF research; * Fund-raisers, securing the money needed to support our efforts; * Advocates, keeping CF a top priority in government, industry and research; * Investors, funding drug discovery and development; * Caregivers, linking patients and families to specialized CF care; and * Family, offering support, information and resources.

Synonyms: CF Foundation

Resource Type: institution

Resource Name: Cystic Fibrosis Foundation

Resource ID: SCR_010726

Alternate IDs: Wikidata: Q649126, ISNI: 0000 0001 0710 9146, grid.427709.f, Crossref funder ID: 100000897, nlx_91994

Alternate URLs: <https://ror.org/00ax59295>

Record Creation Time: 20220129T080300+0000

Ratings and Alerts

No rating or validation information has been found for Cystic Fibrosis Foundation.

No alerts have been found for Cystic Fibrosis Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 95 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Rubin JL, et al. (2025) Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis. *Pulmonary therapy*, 11(3), 365.

Tedman A, et al. (2025) General trends in the calnexin-dependent expression and pharmacological rescue of clinical CFTR variants. *eLife*, 14.

He G, et al. (2025) On the analysis of genetic association with long-read sequencing data. *PLoS genetics*, 21(9), e1011887.

Tedman A, et al. (2025) General Trends in the Calnexin-Dependent Expression and Pharmacological Rescue of Clinical CFTR Variants. *bioRxiv : the preprint server for biology*.

Rong Y, et al. (2025) Partially differentiated ileal and distal-colonic human F508del-cystic fibrosis-enteroids secrete fluid in response to forskolin and linacotide. *iScience*, 28(5), 112453.

Shell SS, et al. (2025) GplR1, an unusual TetR-like transcription factor in *Mycobacterium abscessus*, controls the production of cell wall glycopeptidolipids, colony morphology, and virulence. *mSystems*, 10(9), e0087225.

Shell SS, et al. (2025) GplR1, an unusual TetR-like transcription factor in *Mycobacterium abscessus*, controls the production of cell wall glycopeptidolipids, colony morphology, and virulence. *bioRxiv : the preprint server for biology*.

Calhoun KM, et al. (2025) Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis. *PLoS one*, 20(3), e0309191.

Yarrington KD, et al. (2024) The type IV pilus chemoreceptor PilJ controls chemotaxis of one bacterial species towards another. *PLoS biology*, 22(2), e3002488.

Long DR, et al. (2024) Clinical and in vitro models identify distinct adaptations enhancing *Staphylococcus aureus* pathogenesis in human macrophages. *PLoS pathogens*, 20(7), e1012394.

Da Silva Cunha AL, et al. (2024) Inhibiting CFTR through inh-172 in primary neutrophils reveals CFTR-specific functional defects. *Scientific reports*, 14(1), 31237.

Harris ES, et al. (2024) Reduced sialylation of airway mucin impairs mucus transport by altering the biophysical properties of mucin. *Scientific reports*, 14(1), 16568.

Hinton AC, et al. (2024) Predictors of frequency of CF care in the US Cystic Fibrosis Foundation Patient Registry. *PloS one*, 19(12), e0313510.

Liu CM, et al. (2024) Impact of sinus surgery in people with cystic fibrosis and chronic rhinosinusitis in the era of highly effective modulator therapy: Protocol for a prospective observational study. *PloS one*, 19(9), e0310986.

Plasschaert LW, et al. (2024) Current landscape of cystic fibrosis gene therapy. *Frontiers in pharmacology*, 15, 1476331.

Zamora PF, et al. (2024) Lytic bacteriophages induce the secretion of antiviral and proinflammatory cytokines from human respiratory epithelial cells. *PLoS biology*, 22(4), e3002566.

Santinelli R, et al. (2024) The Inhibition of the Membrane-Bound Transcription Factor Site-1 Protease (MBTP1) Alleviates the p.Phe508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Defects in Cystic Fibrosis Cells. *Cells*, 13(2).

Harris ES, et al. (2024) Reduced Sialylation of Airway Mucin Impairs Mucus Transport by Altering the Biophysical Properties of Mucin. *Research square*.

Oza VH, et al. (2023) Ten simple rules for using public biological data for your research. *PLoS computational biology*, 19(1), e1010749.

Koeppen K, et al. (2023) An rRNA fragment in extracellular vesicles secreted by human airway epithelial cells increases the fluoroquinolone sensitivity of *P. aeruginosa*. *American journal of physiology. Lung cellular and molecular physiology*, 325(1), L54.